You're browsing HLTH 2018's website. Visit hlth.com to explore this year's edition!

Main caricature of Chris Gibson, PhD, who is speaking at HLTH and is Co-Founder & CEO at Recursion Pharmaceuticals Overlay caricature of Chris Gibson, PhD, who is speaking at HLTH and is Co-Founder & CEO at Recursion Pharmaceuticals

Chris Gibson, PhD

Co-Founder & CEO

Recursion Pharmaceuticals



Chris Gibson, PhD, is the Co-Founder and CEO of Recursion Pharmaceuticals, a biotech company leveraging the latest in automation, artificial intelligence and biology to do drug discovery at scale, while pursuing the mission of decoding biology to radically improve lives. Chris developed the technology and approach underlying Recursion as part of his MD/PhD graduate work in the lab of Co-Founder Dr. Dean Li at the University of Utah. Chris left medical school to transform this technology into the rapidly growing company it is today. Chris is a graduate of Rice University with degrees in bioengineering and managerial studies, as well as a graduate of an intense entrepreneurship course at Stanford GSB. He is a Board Member of CureHHT (a patient advocacy group for Hereditary Hemorrhagic Telangiectasia), and a member of the Rare and Undiagnosed Network Advisory Board.